HK1101823A1 - Imidazole derivatives used as tafia inhibitors - Google Patents

Imidazole derivatives used as tafia inhibitors

Info

Publication number
HK1101823A1
HK1101823A1 HK07109537.4A HK07109537A HK1101823A1 HK 1101823 A1 HK1101823 A1 HK 1101823A1 HK 07109537 A HK07109537 A HK 07109537A HK 1101823 A1 HK1101823 A1 HK 1101823A1
Authority
HK
Hong Kong
Prior art keywords
imidazole derivatives
derivatives used
tafia inhibitors
tafia
inhibitors
Prior art date
Application number
HK07109537.4A
Other languages
English (en)
Inventor
Christopher Kallus
Holger Heitsch
Andreas Lindenschmidt
Sven Grueneberg
Hauke Szillat
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1101823(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1101823A1 publication Critical patent/HK1101823A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK07109537.4A 2004-04-22 2007-09-03 Imidazole derivatives used as tafia inhibitors HK1101823A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (fr) 2004-04-22 2005-04-07 Derives d'imidazole servant d'inhibiteurs de tafia

Publications (1)

Publication Number Publication Date
HK1101823A1 true HK1101823A1 (en) 2007-10-26

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07109537.4A HK1101823A1 (en) 2004-04-22 2007-09-03 Imidazole derivatives used as tafia inhibitors

Country Status (35)

Country Link
EP (2) EP1864979B1 (fr)
JP (1) JP4939401B2 (fr)
KR (1) KR101162047B1 (fr)
CN (1) CN100572376C (fr)
AR (1) AR053302A1 (fr)
AT (2) ATE386737T1 (fr)
AU (1) AU2005238144B2 (fr)
BR (1) BRPI0510159A (fr)
CA (1) CA2563401C (fr)
CR (1) CR8650A (fr)
CY (1) CY1108087T1 (fr)
DE (2) DE102004020186A1 (fr)
DK (1) DK1740569T3 (fr)
EC (1) ECSP066941A (fr)
ES (1) ES2299026T3 (fr)
HK (1) HK1101823A1 (fr)
HR (1) HRP20080099T3 (fr)
IL (1) IL178672A (fr)
MA (1) MA28543B1 (fr)
MY (1) MY140903A (fr)
NI (1) NI200600217A (fr)
NO (1) NO20065320L (fr)
NZ (1) NZ550757A (fr)
PE (1) PE20060172A1 (fr)
PL (1) PL1740569T3 (fr)
PT (1) PT1740569E (fr)
RS (1) RS50553B (fr)
RU (1) RU2375356C2 (fr)
SI (1) SI1740569T1 (fr)
TN (1) TNSN06341A1 (fr)
TW (1) TWI359016B (fr)
UA (1) UA87306C2 (fr)
UY (1) UY28868A1 (fr)
WO (1) WO2005105781A1 (fr)
ZA (1) ZA200607668B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537093T3 (es) 2006-12-06 2015-06-02 Sanofi Derivados de sulfamida utilizados como inhibidores de TAFIa
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CA2678069A1 (fr) * 2007-02-13 2008-08-21 Schering Corporation Derives et analogues de chromane en tant qu'agonistes fonctionnellement selectifs des recepteurs adrenergiques alpha2c
BRPI0814294A2 (pt) 2007-07-19 2015-02-03 Metabolex Inc Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
EP2262783A2 (fr) * 2008-02-21 2010-12-22 Sanofi-Aventis Sondes d'imagerie à liaison covalente
JP5531011B2 (ja) * 2008-06-06 2014-06-25 サノフイ ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体
CA2741783A1 (fr) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compose ayant une activite inhibitrice des tafia
RU2538506C2 (ru) * 2009-05-15 2015-01-10 Санофи СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ, ПРИМЕНИМОГО В КАЧЕСТВЕ ИНГИБИТОРА TAFIa
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011041154A1 (fr) 2009-10-01 2011-04-07 Metabolex, Inc. Sels de la tétrazol-1-yl-phénoxyméthyl-thiazol-2-yl-pipéridinyl-pyrimidine substituée
DK2548871T3 (da) 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd Cycloalkylsubstitueret imidazolderivat
JP5778133B2 (ja) * 2010-03-18 2015-09-16 第一三共株式会社 シクロプロパンカルボン酸誘導体
SG189420A1 (en) 2010-11-11 2013-05-31 Sanofi Sa Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
EP2782574B1 (fr) 2011-11-25 2016-03-30 Sanofi Sel du (r) ethyl-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)-propanoate
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
EP2782575B1 (fr) 2011-11-25 2016-04-20 Sanofi Sels cristallins de l'acide (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionique
EP3184095A1 (fr) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Unitées d'administration comprennante une polymorphe 1 de 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
MX2015016961A (es) * 2013-06-10 2016-04-25 Sanofi Sa Derivados de urea macrociclicos como inhibidores de tafia, su preparacion y su uso como productos farmaceuticos.
JPWO2017170460A1 (ja) 2016-03-29 2019-02-07 第一三共株式会社 炎症性腸疾患治療剤
CA3032432A1 (fr) 2016-08-03 2018-02-08 Charles A. Mcwherter Composes d'aryle d'oxymethylene pour le traitement de maladies gastro-intestinales inflammatoires ou de troubles gastro-intestinaux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (fr) * 2001-08-08 2003-02-20 Merck & Co. Inc. Composes anticoagulants
JP2005516972A (ja) 2002-01-22 2005-06-09 ファイザー・インク 血栓疾患の治療のためのｔａｆｉ−ａ阻害剤として使用される３−（イミダゾリル）−２−アミノプロピオン酸

Also Published As

Publication number Publication date
MY140903A (en) 2010-01-29
MA28543B1 (fr) 2007-04-03
PT1740569E (pt) 2008-03-31
RU2375356C2 (ru) 2009-12-10
RS50553B (sr) 2010-05-07
UY28868A1 (es) 2005-11-30
EP1740569A1 (fr) 2007-01-10
ZA200607668B (en) 2008-03-26
RU2006141246A (ru) 2008-06-10
ATE523505T1 (de) 2011-09-15
NZ550757A (en) 2010-06-25
CY1108087T1 (el) 2014-02-12
ES2299026T3 (es) 2008-05-16
ATE386737T1 (de) 2008-03-15
KR101162047B1 (ko) 2012-07-04
EP1740569B1 (fr) 2008-02-20
TWI359016B (en) 2012-03-01
AU2005238144B2 (en) 2010-08-26
SI1740569T1 (sl) 2008-06-30
IL178672A0 (en) 2007-02-11
AU2005238144A1 (en) 2005-11-10
CA2563401C (fr) 2012-08-07
DK1740569T3 (da) 2008-06-02
CR8650A (es) 2007-12-04
CA2563401A1 (fr) 2005-11-10
ECSP066941A (es) 2006-12-20
PE20060172A1 (es) 2006-03-31
IL178672A (en) 2011-08-31
DE502005002927D1 (de) 2008-04-03
UA87306C2 (en) 2009-07-10
JP4939401B2 (ja) 2012-05-23
TNSN06341A1 (en) 2008-02-22
CN1950357A (zh) 2007-04-18
KR20070007346A (ko) 2007-01-15
PL1740569T3 (pl) 2008-07-31
NO20065320L (no) 2007-01-12
NI200600217A (es) 2008-06-17
DE102004020186A1 (de) 2005-11-17
TW200602325A (en) 2006-01-16
EP1864979B1 (fr) 2011-09-07
BRPI0510159A (pt) 2007-10-02
AR053302A1 (es) 2007-05-02
WO2005105781A1 (fr) 2005-11-10
CN100572376C (zh) 2009-12-23
EP1864979A1 (fr) 2007-12-12
JP2007533672A (ja) 2007-11-22
HRP20080099T3 (en) 2008-03-31

Similar Documents

Publication Publication Date Title
HK1101823A1 (en) Imidazole derivatives used as tafia inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
IL194582A0 (en) Condensed imidazole derivatives as aromatase inhibitors
HK1133650A1 (en) Hydantoin derivatives used as mmp inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
EP1790650B1 (fr) Nouveaux dérivés d'imidazoles substitués
HK1135391A1 (en) Triazole derivatives as kinase inhibitors
IL193482A0 (en) Hydantoin based kinase inhibitors
PT1763517E (pt) Derivados de pirimidina como inibidores 11beta-hsd1
ZA200705075B (en) Novel hydantoin derivatives as metalloproteinase inhibitors
ZA200904175B (en) Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)
IL183667A0 (en) Novel hydantoin derivatives as metalloproteinase inhibitors
HK1108435A1 (en) Hydantoin derivatives useful as metalloproteinase inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
SI1937673T1 (sl) Imidazolovi derivati kot inhibitorji TAFIa
SI2104497T1 (sl) Derivati sulfamida kot inhibitorji TAFIa
IL184559A0 (en) Imidazole derivatives
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
ZA200806993B (en) Hydantoin based kinase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150407